OakChart

Acadia Pharmaceuticals Inc

ACADHealthcare·Biotechnology·USA·Mid·NASD·Nov 12 • 3:59 PM ET

18.14-0.23 (-1.25%)
2026-11-13 13:03 CET
Market cap
$3.14B
Revenue, TTM
1,202.30 USD m
Net income, TTM
362.23 USD m
Free cash flow, TTM
81.99 USD m
EPS diluted, TTM
2.10
Price / earnings
8.62
Compare

Price

ACAD against its 20, 50 and 200-day averages
Terms2050200Beat
Patternshover a marker to name it
RS 3Sales 362Price36236315.0020.0025.0030.006.1M12.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ACADclose 18.1420-day 19.8750-day 21.97200-day 23.3718.1452w high 30.9652w low 15.8652-week range, not 6 months

41.4% under the 52-week high of 30.96 on 19 Aug 2026. 52-week low 15.86 on 9 Nov 2026. Last 15 sessions, 42.7% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Setup. RS line 3
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%)
Quality 5 of 5
Value 3 of 4 — fails: P/B: Under 2
Income 2 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%
Small Cap 1 of 4 — fails: Float: Under 100M; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200

Profile

ACAD
52-week range, 15% of the way up
15.8630.96

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

IndexRUT
Employees798
IPOMay 27, 2004
Beta0.89
ATR, 14d1.08
Rel volume0.00
Short float4.88%
Insider own1.31%
Inst own97.21%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap$3.14B
Enterprise Value2.23B
Income362.23M
Sales1.20B
Book / share8.03
Cash / share5.65
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees798
IPOMay 27, 2004

Ratios

Price / earnings8.62
Forward price / earnings17.63
Price / earnings / growth-
Price / sales2.61
Price / book2.26
Price / cash3.21
Price / free cash flow38.24
Value / cash profit16.52
Value / sales1.86
Quick Ratio3.70
Current Ratio3.82
Debt / equity0.05
Long-term debt / equity0.04
Options and shortYes / Yes

Earnings

Earnings / share2.10
Earnings next year1.03
Earnings next quarter0.26
Earnings this year-67.14%
Earnings next year36.17%
Earnings growth, 5 years-11.65%
Past earnings growth- -
Past sales growth27.48% 19.39%
Earnings vs last year36.49%
Sales vs last year14.82%
Earnings vs last quarter-27.48%
Sales vs last quarter22.85%
EarningsNov 04 AMC
Surprise55.62% 2.92%

Ownership

Insiders own1.31%
Insider trades-1.97%
Institutions own97.21%
Institution trades0.15%
Return on assets23.18%
Return on equity31.43%
Return on capital25.07%
Gross Margin90.48%
Operating margin10.17%
Profit Margin30.13%
20-day average-8.72%
50-day average-17.42%
200-day average-22.38%

Technical

Shares out172.79M
Shares floating170.56M
Short / float4.88%
Short ratio3.87
Short interest8.32M
52-week high30.96 -41.4%
52-week low15.86 +14.4%
Volatility11.86% 5.23%
Average range1.08
Strength index37.96
Market sensitivity0.89
Relative volume0.00
Avg Volume2.15M
Volume0

Performance

Perf Week-14.60%
Perf Month-5.77%
Perf Quarter-35.76%
Perf Half Y-17.88%
Perf YTD-32.09%
Perf Year-24.82%
Perf 3Y-18.29%
Perf 5Y-12.15%
Perf 10Y-37.04%
Recommendation1.65
Target Price30.33
Prev Close18.14
Price18.14
Change %0.00%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 13, 2026DowngradeUBSBuy → Neutral$23+26.8%
Mar 25, 2026UpgradeBofA SecuritiesNeutral → Buy$29+59.9%
Feb 24, 2026InitiatedWolfe ResearchOutperform$33+81.9%
Feb 23, 2026UpgradeMizuhoNeutral → Outperform$35+92.9%
Oct 21, 2025InitiatedCitigroupBuy$33+81.9%
May 21, 2025UpgradeDeutsche BankHold → Buy$35+92.9%
Feb 11, 2025InitiatedDeutsche BankHold$22+21.3%
Jan 03, 2025DowngradeGuggenheimBuy → Neutral$23 → $20+10.3%
Oct 10, 2024ResumedRaymond JamesMkt Perform
Aug 07, 2024DowngradeMorgan StanleyOverweight → Equal-Weight$28 → $20+10.3%

Peers

Mkt cap
TickerCompanyMkt cap
AXSMAxsome Therapeutics Inc7.59B
HRMYHarmony Biosciences Holdings Inc1.98B
NBIXNeurocrine Biosciences Inc17.31B
ALKSAlkermes plc7.89B
TSHATaysha Gene Therapies Inc1.36B
JAZZJazz Pharmaceuticals plc15.41B
SUPNSupernus Inc6.07B
XENEXenon Pharmaceuticals Inc4.03B
NGNENeurogene Inc494.75M
BIIBBiogen Inc37.01B

Insider trading

latest 14 of 27
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICEROct 30 '26Sale20.883,32169,34271,322Oct 30 08:20 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 06 '26Option Exercise17.8414,292254,96982,120Aug 07 06:00 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 05 '26Option Exercise17.845,849104,34673,677Aug 07 06:00 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 06 '26Sale29.2214,292417,60467,828Aug 07 06:00 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 05 '26Sale29.005,849169,63867,828Aug 07 06:00 PM
Schneyer Mark C.OfficerAug 05 '26Proposed Sale27.155,849158,800Aug 05 04:49 PM
Thompson Elizabeth H.Z.EVP, Head of Research & DevJul 30 '26Sale26.1316,558432,66318,994Jul 31 06:00 PM
Kihara JamesOfficerJun 26 '26Proposed Sale26.0011,421297,000Jun 26 03:09 PM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 26 '26Sale21.185,401114,39324,509May 27 06:00 PM
JAMES K KIHARAOfficerMay 26 '26Proposed Sale21.185,401114,394May 26 04:02 PM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 04 '26Sale21.791,33229,02429,129May 05 06:00 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERMay 04 '26Sale21.793,50676,39666,145May 05 06:00 PM
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERApr 07 '26Sale22.202,70960,14062,836Apr 07 07:57 PM
Kihara JamesPRINCIPAL ACCOUNTING OFFICERApr 07 '26Sale22.201,03022,86627,865Apr 07 07:55 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 107.13B
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
IWMiShares Russell 2000 Index FundAUM: 77.86B
VBVanguard Morningstar Small-Cap ETFAUM: 80.23B
XBIState Street SPDR S&P Biotech ETFAUM: 10.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.68B
VXFVanguard Extended Market Index ETFAUM: 30.79B
IBBiShares Biotechnology ETFAUM: 11.39B
IWOiShares Russell 2000 Growth ETFAUM: 14.25B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.19B

News

latest 14 of 200

Quarterly earnings

2026Q3 EPS 0.310 beat 0.199, from 0.420 a year earlier. Sales 342.3 beat 332.58, from 278.63 a year earlier
EPS
1.60002024Q4 EPS 0.860 against 0.21624Q42025Q1 EPS 0.110 against 0.08725Q12025Q2 EPS 0.160 against 0.13825Q22025Q3 EPS 0.420 against 0.17325Q32025Q4 EPS 1.600 against 0.13725Q42026Q1 EPS 0.020 against 0.05126Q12026Q2 EPS 0.180 against 0.06826Q22026Q3 EPS 0.310 against 0.19926Q3
Sales, USD millions
342.302024Q4 sales 259.6 against 255.6124Q42025Q1 sales 244.32 against 238.7725Q12025Q2 sales 264.57 against 262.0225Q22025Q3 sales 278.63 against 276.5425Q32025Q4 sales 283.99 against 292.7925Q42026Q1 sales 268.1 against 280.2526Q12026Q2 sales 307.96 against 296.5526Q22026Q3 sales 342.3 against 332.5826Q3

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2026Q3ended 2026-09-302026-11-04 16:300.3100.1990.310342.3332.58EPS +55.6% · sales +2.9%vs 2025Q3, year-ago quarter · EPS -26.2% · sales +22.8%20 EPS · 18 salesOpen +2.38% vs SPY -0.17%. Close -1.07% vs SPY -4.41%
2026Q2ended 2026-06-302026-08-04 16:300.1800.0680.182307.96296.55EPS +163.9% · sales +3.8%vs 2025Q2, year-ago quarter · EPS +12.5% · sales +16.4%21 EPS · 20 salesOpen +2.97% vs SPY +0.59%. Close +6.08% vs SPY -0.20%
2026Q1ended 2026-03-312026-05-06 16:300.0200.0510.021268.1280.25EPS -60.4% · sales -4.3%vs 2025Q1, year-ago quarter · EPS -81.8% · sales +9.7%20 EPS · 19 salesOpen +1.91% vs SPY +0.17%. Close +5.03% vs SPY -0.31%
2025Q4ended 2025-12-312026-02-25 16:301.6000.1371.597283.99292.79EPS +1067.9% · sales -3.0%vs 2024Q4, year-ago quarter · EPS +86.0% · sales +9.4%21 EPS · 20 salesOpen -5.33% vs SPY +0.02%. Close -1.32% vs SPY -0.56%
2025Q3ended 2025-09-302025-11-05 16:300.4200.1730.421278.63276.54EPS +142.9% · sales +0.8%vs 2024Q3, year-ago quarter · EPS +110.0% · sales +11.3%20 EPS · 19 salesOpen +5.60% vs SPY -0.16%. Close -3.05% vs SPY -1.07%
2025Q2ended 2025-06-302025-08-06 16:300.1600.1380.158264.57262.02EPS +15.9% · sales +1.0%vs 2024Q2, year-ago quarter · EPS -20.0% · sales +9.3%19 EPS · 18 salesOpen +1.09% vs SPY +0.55%. Close +2.52% vs SPY -0.08%
2025Q1ended 2025-03-312025-05-07 16:300.1100.0870.113244.32238.77EPS +26.9% · sales +2.3%vs 2024Q1, year-ago quarter · EPS +10.0% · sales +18.7%19 EPS · 18 salesOpen -0.61% vs SPY +0.73%. Close +14.31% vs SPY +0.70%
2024Q4ended 2024-12-312025-02-26 16:300.8600.2160.862259.6255.61EPS +298.7% · sales +1.6%vs 2023Q4, year-ago quarter · EPS +207.1% · sales +12.4%20 EPS · 16 salesOpen +2.32% vs SPY +0.39%. Close +1.79% vs SPY -1.60%
2024Q3ended 2024-09-302024-11-06 16:300.2000.1380.197250.4248.83EPS +44.8% · sales +0.6%vs 2023Q3, year-ago quarter · EPS -150.0% · sales +18.3%19Open -0.63% vs SPY +0.35%. Close +8.93% vs SPY +0.77%
2024Q2ended 2024-06-302024-08-06 16:300.2000.1780.201241.96235.95EPS +12.5% · sales +2.6%vs 2023Q2, year-ago quarter · EPS +1900.0% · sales +46.4%20 EPS · 19 salesOpen -18.30% vs SPY +1.21%. Close -19.52% vs SPY -0.67%
2024Q1ended 2024-03-312024-05-08 16:300.1000.0490.099205.83208.31EPS +104.9% · sales -1.2%vs 2023Q1, year-ago quarter · EPS -137.0% · sales +73.8%19Open +2.16% vs SPY +0.04%. Close -11.21% vs SPY +0.58%
2023Q4ended 2023-12-312024-02-27 16:300.2800.2890.275231.04223.79EPS -3.1% · sales +3.2%vs 2022Q4, year-ago quarter · EPS -207.7% · sales +69.3%20Open -6.53% vs SPY -0.32%. Close -9.92% vs SPY -0.13%
2023Q3ended 2023-09-302023-11-02 16:30-0.400-0.448-0.397211.7192.32EPS -10.7% · sales +10.1%vs 2022Q3, year-ago quarter · EPS +135.3% · sales +62.0%17 EPS · 16 sales-
2023Q2ended 2023-06-302023-08-02 16:300.010-0.0980.007165.24166.18EPS -110.2% · sales -0.6%vs 2022Q2, year-ago quarter · EPS -104.8% · sales +22.8%16 EPS · 13 sales-
2023Q1ended 2023-03-312023-05-08 16:30-0.270-0.215-0.265118.46120.06EPS +25.9% · sales -1.3%vs 2022Q1, year-ago quarter · EPS -61.4% · sales +2.6%18 EPS · 16 sales-
2022Q4ended 2022-12-312023-02-27 16:30-0.260-0.247-0.258136.49134.23EPS +5.2% · sales +1.7%vs 2021Q4, year-ago quarter · EPS -3.7% · sales +4.4%21 EPS · 18 sales-

Annual earnings

2025FY EPS 2.300 beat 0.809, from 1.360 a year earlier. Sales 1,072 missed 1,081, from 957.8 a year earlier
EPS
2.3000-1.9912018FY EPS -1.940 against -1.99120182019FY EPS -1.600 against -1.61820192020FY EPS -1.790 against -1.84020202021FY EPS -1.050 against -1.02020212022FY EPS -1.340 against -1.31520222023FY EPS -0.370 against -0.35820232024FY EPS 1.360 against 0.72120242025FY EPS 2.300 against 0.8092025
Sales, USD millions
1,08102018FY sales 223.81 against 223.7320182019FY sales 339.1 against 337.5420192020FY sales 441.76 against 443.7520202021FY sales 484.15 against 487.9820212022FY sales 517.24 against 514.7920222023FY sales 726.44 against 719.1720232024FY sales 957.8 against 968.6320242025FY sales 1,072 against 1,0812025

Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.

earnings feed, not the snapshot. Not the statement ratio.

PeriodEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mP/E, earnings feed
2030FYestimate-2.515--1,8417.21
2029FYestimate-1.857--1,7029.77
2028FYestimate-1.586--1,60111.44
2027FYestimate-1.029--1,44417.63
2026FYestimate-0.756--1,28024.00
2025FY2.3000.8092.3001,0721,08111.61
2024FY1.3600.7211.361957.8968.6313.49
2023FY-0.370-0.358-0.374726.44719.17-
2022FY-1.340-1.315-1.336517.24514.79-
2021FY-1.050-1.020-1.046484.15487.98-
2020FY-1.790-1.840-1.790441.76443.75-
2019FY-1.600-1.618-1.598339.1337.54-
2018FY-1.940-1.991-1.937223.81223.73-
2017FY-2.360-2.397-2.360124.9126.57-
2016FY-2.340-2.342-2.34017.3314.41-
2015FY-1.630-1.583-1.6300.060.97-
2014FY-0.950-0.912-0.9500.120.10-
2013FY-0.440-0.450-0.4401.151.30-
2012FY-0.380-0.352-0.3804.915.01-
2011FY-0.440-0.435-0.4402.072.05-
2010FY0.3900.3200.39042.1442.4746.51

Quarterly results

2026Q3 revenue 342.29, from 278.63 a year earlier. Operating margin 21.0%, from 12.8% a year earlier
Revenue, USD millions
342.2902024Q4 revenue 259.624Q42025Q1 revenue 244.3225Q12025Q2 revenue 264.5725Q22025Q3 revenue 278.6325Q32025Q4 revenue 283.9925Q42026Q1 revenue 268.0626Q12026Q2 revenue 307.9626Q22026Q3 revenue 342.2926Q3
Operating margin
21.00-1.72024Q4 operating margin 2.7%24Q42025Q1 operating margin 7.9%25Q12025Q2 operating margin 12.2%25Q22025Q3 operating margin 12.8%25Q32025Q4 operating margin 6.1%25Q42026Q1 operating margin -1.7%26Q12026Q2 operating margin 12.3%26Q22026Q3 operating margin 21.0%26Q3

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type. 2026FY E 0.76 per share.
PeriodTypeScaleDateMeanvs prior date
2026FYEper share2026-11-130.76-0.1%
2026Q4Eper share2026-11-130.26-1.6%
2026FYRper share2026-11-130.76-0.1%
2026Q4Rper share2026-11-130.26-1.6%
2026FYSUSD millions2026-11-131,280+0.1%
2026Q4S-2026-11-13362.4-0.2%
2026Q3Eper share2026-10-280.200.0%
2026Q3Rper share2026-10-280.200.0%
2026Q3S-2026-10-28332.580.0%
2026Q2Eper share2026-07-270.06-1.7%
2026Q2Rper share2026-07-270.06-1.7%
2026Q2S-2026-07-22295.510.0%
2026Q1Eper share2026-04-290.05+2.0%
2026Q1Rper share2026-04-290.05+2.0%
2026Q1S-2026-04-29280.25+0.1%
2025FYEper share2026-02-220.810.0%
2025Q4Eper share2026-02-220.140.0%
2025FYRper share2026-02-220.810.0%
2025Q4Rper share2026-02-220.140.0%
2025FYSUSD millions2026-02-201,0810.0%
2025Q4S-2026-02-20292.79+0.0%
2025Q3S-2025-10-30276.540.0%
2025Q3Eper share2025-10-220.14-2.4%
2025Q3Rper share2025-10-220.14-2.4%
2025Q2Eper share2025-08-040.14-0.4%
2025Q2Rper share2025-08-040.14-0.4%
2025Q2S-2025-08-04262.020.0%
2025Q1Eper share2025-05-020.09+158.8%
2025Q1Rper share2025-05-020.09+158.8%
2025Q1S-2025-05-02238.77-0.1%
2024FYEper share2025-02-200.72+0.1%
2024FYRper share2025-02-200.72+0.1%
2024Q4S-2025-02-19255.61-2.4%
2024FYS-2025-02-10968.63+0.0%
2024Q4Eper share2025-02-070.22-1.6%
2024Q4Rper share2025-02-070.22-1.6%
2024Q3Eper share2024-10-300.140.0%
2024Q3Rper share2024-10-300.140.0%
2024Q3S-2024-10-21248.83+0.1%
2024Q2Eper share2024-07-300.18-1.9%
2024Q2Rper share2024-07-300.18-1.9%
2024Q2S-2024-07-30235.95+0.1%
2024Q1Eper share2024-05-030.05-2.2%
2024Q1Rper share2024-05-030.05-2.2%
2024Q1S-2024-05-03208.310.0%
2023FYEper share2024-02-27-0.360.0%
2023FYRper share2024-02-27-0.360.0%
2023FYS-2024-02-05719.170.0%

Estimate history

Annual
Metric201720182019202020212022202320242025TTMMRQ
EPS per share-2.36-1.937-1.598-1.79-1.046-1.336-0.3741.3612.3012.1048-
Sales USD millions1252243394424845177269581,0721,202-
Shares million shares124144155160161162165167170-173
Quarterly
MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
EPS per share0.1970.8620.1130.1580.4211.5970.0210.1820.305
Sales USD millions250260244265279284268308342
Shares million shares166167167169169170171172173

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Total Revenue1,202.301,071.51+11.9%957.80+31.8%726.44+40.4%517.24+6.8%484.14+9.6%441.75+30.3%339.08+51.5%223.81
Cost of Goods Sold Incl. D&A114.4299.89+3.2%96.80+111.7%45.73+349.7%10.17-14.9%11.95+2.2%11.69+3.1%11.34-8.4%12.38
Gross Profit1,087.88971.62+12.8%860.99+26.5%680.71+34.2%507.07+7.4%472.19+9.8%430.07+31.2%327.73+55.0%211.43
Selling, General and Administrative Excl. Other965.55866.81+11.6%776.71+3.0%754.09+3.2%730.66+13.7%642.63-3.2%663.85+15.6%574.28+25.2%458.87
Research and Development319.46328.80+8.4%303.25-13.8%351.62-2.8%361.57+51.0%239.41-10.1%266.33+10.8%240.38+28.4%187.16
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income122.33104.81+24.4%84.28-73.38-223.60-170.44-233.79-246.54-247.44
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.00-0.000.00-100.0%52.80--
Net Income Before Taxes157.21138.90-46.2%258.07-51.04-213.44-167.52-280.97-234.38-243.94
Income Taxes-205.02-252.10-897.3%31.62+208.5%10.25+305.1%2.53+622.9%0.35-42.6%0.61-30.7%0.88-30.2%1.26
Consolidated Net Income362.23391.00+72.7%226.45-61.29-215.97-167.87-281.58-235.26-245.19
Net Income From Continuing Operations362.23391.00+72.7%226.45-61.29-215.97-167.87-281.58-235.26-245.19
Net Income362.23391.00+72.7%226.45-61.29-215.97-167.87-281.58-235.26-245.19
EPS (Recurring) per share2.062.30+69.1%1.36-0.37-1.34-1.05-1.55-1.60-1.94
EPS (Basic, Before Extraordinaries) per share2.132.32+69.3%1.37-0.37-1.34-1.05-1.79-1.60-1.94
EPS (Diluted) per share2.102.30+69.1%1.36-0.37-1.34-1.05-1.79-1.60-1.94
EBITDA135.06116.57+16.4%100.16-67.83-221.57-167.09-230.85-243.78-244.44
Non-Operating Income (Expense)34.8834.09-80.4%173.80+678.0%22.34+120.1%10.15+247.6%2.92-48.0%5.61-53.9%12.16+246.4%3.51
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense49.2441.19-22.2%52.97+1.0%52.47-2.6%53.88+16.0%46.44-24.6%61.63+2.6%60.05-6.8%64.44
Price To Earnings Ratio ratio statement ratio, not the snapshot8.628.6223.75------
Price To Sales Ratio ratio2.944.243.197.064.987.7419.0418.579.15
Gross Margin %90.4890.6889.8993.7098.0397.5397.3596.6594.47
Operating Margin %10.179.788.80-10.10-43.23-35.20-52.92-72.71-110.56
Net Margin %30.1336.4923.64-8.44-41.76-34.67-63.74-69.38-109.56
Shares Outstanding million shares172.79170.31+2.2%166.71+1.3%164.65+1.6%162.06+0.7%161.01+0.9%159.64+2.8%155.28+7.9%143.85
Market Capitalization3,135.123,135.12+2.7%3,053.29-40.6%5,140.48+99.4%2,577.94-31.3%3,752.05-55.9%8,498.96+29.0%6,589.19+183.7%2,322.43

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Total Revenue342.29+22.8%307.96+16.4%268.06+9.7%283.99+9.4%278.63+11.3%264.57+9.3%244.32+18.7%259.60+12.4%
Cost of Goods Sold Incl. D&A35.09+62.1%28.32+36.6%24.79+21.6%26.23+20.3%21.65+14.8%20.73+13.7%20.39-11.2%21.80+21.9%
Gross Profit307.20+19.5%279.64+14.7%243.27+8.6%257.76+8.4%256.99+11.0%243.83+9.0%223.93+22.4%237.80+11.6%
Selling, General and Administrative Excl. Other235.48+6.4%241.81+14.4%247.89+21.1%240.37+4.1%221.23+10.7%211.46+9.4%204.63+22.0%230.81+29.5%
Research and Development76.28-13.2%81.56+4.6%76.87-1.8%84.76-15.9%87.83+31.9%77.95+2.3%78.27+31.1%100.73+50.9%
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income71.72+100.6%37.84+16.9%-4.62-124.0%17.39+148.8%35.76+13.0%32.37+6.3%19.29+26.8%6.99-80.0%
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes80.44+80.4%46.47+15.6%3.98-85.7%26.32-83.7%44.59+14.9%40.21+8.1%27.78+32.3%161.09+305.8%
Income Taxes26.9114.97+10.6%0.34-96.1%-247.25-1525.9%-27.18-550.0%13.54+257.3%8.79+97.5%17.34
Consolidated Net Income53.52-25.4%31.50+18.1%3.64-80.8%273.57+90.3%71.78+119.0%26.67-20.1%18.99+14.7%143.74+213.8%
Net Income From Continuing Operations53.52-25.4%31.50+18.1%3.64-80.8%273.57+90.3%71.78+119.0%26.67-20.1%18.99+14.7%143.74+213.8%
Net Income53.52-25.4%31.50+18.1%3.64-80.8%273.57+90.3%71.78+119.0%26.67-20.1%18.99+14.7%143.74+213.8%
EPS (Recurring) per share0.31-26.2%0.18+12.5%0.02-81.8%1.60+86.0%0.42+110.0%0.16-20.0%0.11+10.0%0.86+207.1%
EPS (Basic, Before Extraordinaries) per share0.31-27.9%0.18+12.5%0.02-81.8%1.62+88.4%0.43+115.0%0.16-20.0%0.11+10.0%0.86+207.1%
EPS (Diluted) per share0.30-28.6%0.18+12.5%0.02-81.8%1.60+86.0%0.42+110.0%0.16-20.0%0.11+10.0%0.86+207.1%
EBITDA75.37+94.7%40.99+16.1%-1.62-107.3%20.32+66.6%38.71+13.2%35.31+7.0%22.24+7.2%12.20-66.6%
Non-Operating Income (Expense)8.72-1.4%8.64+10.2%8.60+1.3%8.93-94.2%8.84+23.5%7.84+16.1%8.49+46.6%154.10+3137.4%
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense13.79+32.5%13.38+18.1%11.61+29.1%10.46+26.6%10.41-49.6%11.33-8.6%8.99-22.8%8.26-42.0%
Price To Earnings Ratio ratio statement ratio, not the snapshot8.6211.529.7317.1816.0415.7012.2223.75
Price To Sales Ratio ratio2.943.843.514.273.483.572.803.19
Gross Margin %89.7590.8190.7590.7792.2392.1691.6591.60
Operating Margin %20.9512.29-1.726.1212.8312.247.902.69
Net Margin %15.6410.231.3696.3325.7610.087.7755.37
Shares Outstanding million shares172.79+2.2%172.13+2.1%171.09+2.4%170.31+2.2%169.15+1.7%168.61+1.7%167.12+1.3%166.71+1.3%
Market Capitalization3,135.12-12.9%4,332.27+20.0%3,795.22+37.0%4,518.85+48.0%3,600.31+41.1%3,610.00+34.5%2,770.37-9.1%3,053.29-40.6%

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/20182017FY12/31/2017
Cash & Short Term Investments819.69+8.4%755.99+72.3%438.87+5.3%416.82-20.0%520.71-17.6%631.96-9.4%697.43+47.3%473.52+38.7%341.34
Short Term Receivables148.23+41.6%104.69+2.3%102.35+62.3%63.08-3.5%65.34+30.0%50.28+32.8%37.87+36.3%27.79+50.8%18.43
Inventories34.67+57.9%21.95-38.7%35.82+439.5%6.64-15.7%7.88-18.6%9.68+52.7%6.34+55.8%4.07-22.5%5.25
Other Current Assets59.53+6.9%55.68+42.4%39.09+82.7%21.40-10.4%23.89-7.0%25.69+38.0%18.61-10.2%20.73+145.0%8.46
Total Current Assets1,062.11+13.2%938.32+52.3%616.12+21.3%507.94-17.8%617.82-13.9%717.62-5.6%760.25+44.5%526.11+40.9%373.48
Net Property, Plant & Equipment54.87+8.0%50.79-10.1%56.47-8.3%61.59-7.1%66.31+17.5%56.44+344.4%12.70+283.7%3.31+24.4%2.66
Total Investments and Advances7.84-10.6%8.77+52.0%5.77-55.5%12.97+38.4%9.37+32.5%7.07-0.3%7.09+46.8%4.83+94.8%2.48
Intangible Assets108.89-9.1%119.78+82.9%65.49-0.00-100.0%1.11-57.0%2.58-36.5%4.06-26.7%5.54
Deferred Tax Assets249.88--------
Other Assets80.60+15.0%70.10+1274.5%5.10-4.0%5.31-19.7%6.61+1639.5%0.38-32.1%0.56-70.5%1.90+442.9%0.35
Total Assets1,564.19+31.7%1,187.76+58.6%748.96+27.4%587.81-16.0%700.12-10.5%782.62-0.1%783.18+45.0%540.20+40.5%384.51
Short Term Debt Incl. Current Port. of LT Debt11.63+16.8%9.96+6.0%9.40+1.1%9.30+12.0%8.30+63.1%5.09+48.4%3.430.000.00
Accounts Payable10.90-32.7%16.19-7.7%17.54+37.6%12.75+85.3%6.88-19.0%8.49+17.6%7.22+127.8%3.17-63.9%8.79
Income Tax Payable0.30-97.5%12.02+670.5%1.56------
Other Current Liabilities254.27-28.7%356.70+58.0%225.74+117.9%103.58+28.1%80.89-12.4%92.39+44.0%64.17+13.8%56.40+40.2%40.24
Total Current Liabilities277.11-29.8%394.87+55.3%254.25+102.4%125.63+30.8%96.07-9.3%105.97+41.6%74.83+25.6%59.56+21.5%49.03
Long Term Debt40.55-3.5%42.04-12.1%47.80-9.3%52.70-6.1%56.13+26.2%44.46+599.1%6.360.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities19.14+6.0%18.06+19.2%15.15+67.0%9.07+29.0%7.03+35.7%5.18+81.1%2.86+83.3%1.56+721.1%0.19
Total Liabilities336.81-26.0%454.96+43.4%317.20+69.3%187.40+17.7%159.23+2.3%155.61+85.1%84.05+37.5%61.12+24.2%49.22
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,227.39+67.5%732.79+69.7%431.75+7.8%400.41-26.0%540.89-13.7%627.01-10.3%699.13+45.9%479.08+42.9%335.29
Total Shareholders Equity1,227.39+67.5%732.79+69.7%431.75+7.8%400.41-26.0%540.89-13.7%627.01-10.3%699.13+45.9%479.08+42.9%335.29
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,227.39+67.5%732.79+69.7%431.75+7.8%400.41-26.0%540.89-13.7%627.01-10.3%699.13+45.9%479.08+42.9%335.29
Total Liabilities & Stockholders Equity1,564.19+31.7%1,187.76+58.6%748.96+27.4%587.81-16.0%700.12-10.5%782.62-0.1%783.18+45.0%540.20+40.5%384.51
Book Value Per Share per share7.21+63.9%4.40+67.9%2.62+6.1%2.47-26.5%3.36-14.5%3.93-12.7%4.50+35.1%3.33+23.8%2.69
Tangible Book Value Per Share per share6.57+78.5%3.68+65.8%2.22-10.1%2.47-26.5%3.36-14.3%3.92-12.7%4.49+36.1%3.30+24.5%2.65
Full-Time Employees people798+22.0%654+9.4%598+16.6%513-0.2%514-14.5%601+19.5%503+17.0%430+1.2%425
Price to Book Ratio ratio2.265.2914.186.056.9513.619.504.869.79
Return on Assets %28.4223.39-9.17-33.54-22.64-35.97-35.55-53.03-61.21
Return on Equity %39.8938.89-14.73-45.89-28.75-42.47-39.93-60.22-67.80
Return on Invested Capital %30.8429.23-12.78-47.67-28.12-41.94-33.35-51.18-86.32
Quick Ratio ratio3.712.322.283.996.356.6810.088.767.51
Current Ratio ratio3.832.382.424.046.436.7710.168.837.62

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Net Income362.23391.00+72.7%226.45-61.29-215.97-167.87-281.58-235.26-245.19
Depreciation12.7311.76-25.9%15.88+186.1%5.55+173.4%2.03-39.2%3.34+14.0%2.93+5.8%2.77-7.7%3.00
Other Funds (Non Cash)61.1846.71-88.77-263.5%54.30-12.3%61.92-2.8%63.69-51.5%131.45+69.3%77.66-6.3%82.91
Funds from Operations210.33199.59+30.0%153.56-1.43-152.03-100.84-147.20-154.84-159.27
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-112.80-89.76-2257.7%4.16-77.1%18.13-52.3%37.99-24.82-324.8%11.04+197.6%3.71-8.20
Cash from Operating Activities97.53109.84-30.4%157.72+844.4%16.70-114.03-125.66-136.17-151.13-167.47
Capital Expenditures-15.55-103.53-0.52-40.050.00-1.12-7.59-1.13-2.15
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-100.0%0.04
Purchase or Sale of Investments-68.72-199.04-30.02-141.7%72.05-1.6%73.24-69.98-135.0%200.10-164.71-69.39
Purchase of Investments-434.28-692.57-505.10-369.99-363.17-492.80-339.91-578.63-331.06
Sale Or Maturity of Investments365.56493.53+3.9%475.08+7.5%442.03+1.3%436.42+3.2%422.82-21.7%540.00+30.5%413.93+58.2%261.68
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-84.27-302.56-30.54-195.4%32.00-56.3%73.24-71.10-136.9%192.51-165.84-71.49
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock49.2649.88+629.2%6.84-72.8%25.13+206.5%8.20-54.8%18.16-77.6%81.00-78.2%371.85+21.3%306.65
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock49.2649.88+629.2%6.84-72.8%25.13+206.5%8.20-54.8%18.16-77.6%81.00-78.2%371.85+21.3%306.65
Proceedsfrom Stock Options49.2649.88+629.2%6.84-72.8%25.13+206.5%8.20-54.8%18.16-77.6%81.00-78.2%371.85+21.3%306.65
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities49.2649.88+629.2%6.84-72.8%25.13+206.5%8.20-54.8%18.16-77.6%81.00-78.2%371.85+21.3%306.65
Exchange Rate Effect0.220.03-0.09-0.02-300.0%0.010.0%0.01-0.010.000.00
Net Change in Cash62.74-142.82-206.6%133.93+81.5%73.81-32.59-178.59-230.0%137.33+150.2%54.88-18.9%67.69
Free Cash Flow81.99105.15-33.1%157.20+844.1%16.65-114.03-126.78-143.75-152.26-169.62
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow ratio43.1243.1619.42308.02-----
Deferred Taxes & Investment Tax Credit--249.880.000.000.000.000.000.000.00

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Cash & Short Term Investments976.45+15.3%956.47+25.5%851.46+24.9%819.69+8.4%847.02+49.8%762.00+52.1%681.58+44.9%755.99+72.3%
Short Term Receivables178.31+27.9%166.33+39.0%148.38+30.5%148.23+41.6%139.44+26.4%119.69+8.4%113.71+13.6%104.69+2.3%
Inventories40.36+38.7%32.37+23.9%31.57+37.6%34.67+57.9%29.10-52.3%26.12-63.5%22.95-62.9%21.95-38.7%
Other Current Assets73.31+20.4%69.37+31.5%64.60+22.6%59.53+6.9%60.87+18.1%52.75+14.5%52.70+23.2%55.68+42.4%
Total Current Assets1,268.43+17.8%1,224.55+27.5%1,096.02+25.8%1,062.11+13.2%1,076.42+36.6%960.55+31.8%870.94+29.0%938.32+52.3%
Net Property, Plant & Equipment85.87+60.9%86.53+58.7%60.93+12.6%54.87+8.0%53.38+10.7%54.54-3.5%54.11-7.7%50.79-10.1%
Total Investments and Advances7.85-17.1%7.85-17.1%7.85-10.5%7.84-10.6%9.47+8.0%9.47+64.1%8.77+52.0%8.77+52.0%
Intangible Assets135.48+21.4%103.45-9.5%106.17-9.3%108.89-9.1%111.61+5.8%114.34+6.0%117.06+6.2%119.78+82.9%
Deferred Tax Assets226.72240.68249.62249.88----
Other Assets69.81-12.6%79.85-7.9%84.65+3.9%80.60+15.0%79.88+206.5%86.66+477.0%81.48+1473.0%70.10+1274.5%
Total Assets1,794.15+34.8%1,742.90+42.2%1,605.23+41.8%1,564.19+31.7%1,330.77+36.2%1,225.56+34.1%1,132.36+32.4%1,187.76+58.6%
Short Term Debt Incl. Current Port. of LT Debt14.53+23.3%14.31+22.4%11.79+3.7%11.63+16.8%11.78+31.6%11.69+11.7%11.37+8.8%9.96+6.0%
Accounts Payable16.33-24.9%44.57+121.7%12.25-32.3%10.90-32.7%21.75+14.0%20.10+1.1%18.09-6.4%16.19-7.7%
Income Tax Payable---0.30-97.5%--9.05+19.2%12.02+670.5%
Other Current Liabilities301.36-6.7%302.56+1.5%281.49+6.6%254.27-28.7%323.05+2.3%298.23-0.3%264.01-10.0%356.70+58.0%
Total Current Liabilities332.22-6.8%361.44+9.5%305.52+1.0%277.11-29.8%356.58+3.7%330.02-2.3%302.53-8.5%394.87+55.3%
Long Term Debt57.32+33.2%59.55+33.5%39.00-12.6%40.55-3.5%43.03+6.5%44.60-5.5%44.63-9.3%42.04-12.1%
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities17.12+23.3%15.31-46.4%12.64-36.7%19.14+6.0%13.89-9.3%28.55+131.0%19.96+77.1%18.06+19.2%
Total Liabilities406.66-1.7%436.29+8.2%357.16-2.7%336.81-26.0%413.50+3.5%403.17+1.5%367.13-6.1%454.96+43.4%
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity1,387.49+51.3%1,306.61+58.9%1,248.07+63.1%1,227.39+67.5%917.27+58.9%822.38+59.2%765.24+64.9%732.79+69.7%
Total Shareholders Equity1,387.49+51.3%1,306.61+58.9%1,248.07+63.1%1,227.39+67.5%917.27+58.9%822.38+59.2%765.24+64.9%732.79+69.7%
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity1,387.49+51.3%1,306.61+58.9%1,248.07+63.1%1,227.39+67.5%917.27+58.9%822.38+59.2%765.24+64.9%732.79+69.7%
Total Liabilities & Stockholders Equity1,794.15+34.8%1,742.90+42.2%1,605.23+41.8%1,564.19+31.7%1,330.77+36.2%1,225.56+34.1%1,132.36+32.4%1,187.76+58.6%
Book Value Per Share per share8.03+48.2%7.59+55.5%7.29+59.2%7.21+63.9%5.42+56.2%4.88+56.4%4.58+63.0%4.40+67.9%
Tangible Book Value Per Share per share7.25+52.3%6.99+66.4%6.67+71.9%6.57+78.5%4.76+67.6%4.20+70.0%3.88+80.5%3.68+65.8%
Full-Time Employees people---798+22.0%---654+9.4%
Price to Book Ratio ratio2.263.473.094.934.384.713.785.29
Return on Assets %23.1825.6427.4428.4222.6420.7723.0323.39
Return on Equity %31.4335.7437.3239.8934.9533.1837.2438.89
Return on Invested Capital %3.702.310.2821.587.473.082.3418.55
Quick Ratio ratio3.703.303.483.712.942.832.802.32
Current Ratio ratio3.823.393.593.833.022.912.882.38

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Net Income53.52-25.4%31.50+18.1%3.64-80.8%273.57+90.3%71.78+119.0%26.67-20.1%18.99+14.7%143.74+213.8%
Depreciation3.65+23.7%3.16+7.5%2.99+1.4%2.92-44.0%2.95+14.8%2.94+14.4%2.95-46.7%5.21+217.7%
Other Funds (Non Cash)17.48+44.7%16.89+32.0%14.24+53.8%12.5612.08-48.4%12.80-6.8%9.26-28.5%-138.88-955.2%
Funds from Operations89.05+2.6%61.32+44.6%20.78-33.4%39.18+289.1%86.81+47.8%42.41-14.7%31.20-11.0%10.07-84.2%
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-77.5539.46+83.1%13.20-87.91-390.0%-12.52-378.8%21.55-10.8830.31+39.6%
Cash from Operating Activities11.50-84.5%100.78+57.6%33.98+67.2%-48.73-220.7%74.29+17.5%63.96+155.7%20.32-30.1%40.38-52.7%
Capital Expenditures-1.24-5.09-5.21-4.00-0.39-0.30-98.84-0.45
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-84.91-3.4471.49-51.86-142.3%-78.96-43.00-25.21122.60
Purchase of Investments-168.22-93.44-15.01-157.61-204.55-174.39-156.01-135.76
Sale Or Maturity of Investments83.31-33.7%90.00-31.5%86.50-33.9%105.75-59.1%125.59+81.8%131.39+61.2%130.80+97.9%258.37+149.0%
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-86.15-8.5366.28-55.87-145.7%-79.35-43.29-124.05122.15
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock11.87+26.0%10.49-34.3%4.23+129.9%22.67+1050.8%9.42+3388.9%15.96+348.3%1.84+76.9%1.97-63.7%
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock11.87+26.0%10.49-34.3%4.23+129.9%22.67+1050.8%9.42+3388.9%15.96+348.3%1.84+76.9%1.97-63.7%
Proceedsfrom Stock Options11.87+26.0%10.49-34.3%4.23+129.9%22.67+1050.8%9.42+3388.9%15.96+348.3%1.84+76.9%1.97-63.7%
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities11.87+26.0%10.49-34.3%4.23+129.9%22.67+1050.8%9.42+3388.9%15.96+348.3%1.84+76.9%1.97-63.7%
Exchange Rate Effect0.160.03+50.0%0.030.010.000.02-0.01-200.0%-0.06
Net Change in Cash-62.62-1536.2%102.77+180.5%104.52-81.93-149.8%4.3636.64-101.89-733.3%164.44+81.8%
Free Cash Flow10.26-86.1%95.69+50.3%28.77+41.6%-52.74-232.1%73.90+17.0%63.66+154.5%20.32-30.1%39.93-53.2%
Price to Free Cash Flow ratio43.1230.0333.8443.5318.4119.4518.7619.46

Revenue breakdown

USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.

Product
Name20242025vs 20242025 share
DAYBUE348.41391.42+12.3%36.5%
NUPLAZID609.39680.09+11.6%63.5%
Total957.801,071.51+11.9%100.0%
Region
Name20242025vs 20242025 share
United States957.801,071.51+11.9%100.0%
Total957.801,071.51+11.9%100.0%

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.88%8.3M170.6M1.87M
2026-10-155.35%9.1M170.0M1.86M
2026-09-304.87%8.3M170.0M1.77M
2026-09-155.69%9.7M170.0M1.67M
2026-08-315.73%9.7M170.0M1.61M
2026-08-145.57%9.5M170.0M1.62M
2026-07-316.36%10.8M170.1M1.61M
2026-07-156.52%11.0M169.1M1.70M
2026-06-306.48%11.0M169.1M1.72M
2026-06-156.99%11.8M169.0M1.70M
2026-05-296.96%11.8M169.0M1.82M
2026-05-156.76%11.4M169.0M1.91M
2026-04-306.61%11.2M168.7M1.82M
2026-04-156.54%11.0M168.0M1.72M
2026-03-316.34%10.6M167.9M1.68M
2026-03-135.14%8.6M167.9M1.50M
2026-02-275.65%9.5M167.9M1.46M
2026-02-135.34%8.9M166.6M1.36M
2026-01-305.57%9.3M167.4M1.43M
2026-01-155.00%8.4M167.4M1.51M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call13.003.107.300.004.6620.000.000.946-0.0290.003
call14.002.106.305.904.21761.000.000.917-0.0370.004
call15.001.105.100.003.4390.000.000.898-0.0340.005
call16.000.204.300.003.1450.000.000.869-0.0310.006
call17.000.003.400.742.7321.000.000.709-0.0550.009
call18.000.350.700.650.5871673.000.552-0.0600.011
call19.000.002.350.250.98722.000.000.453-0.0950.011
call20.000.000.950.131.2932680.000.339-0.0810.010
call21.000.000.050.101.2857,0690.000.261-0.0710.009
call22.000.000.750.010.8014,0302.000.057-0.0160.003
call23.000.000.450.421.69460.000.000.215-0.0840.008
call24.000.002.150.151.07453.000.000.045-0.0170.003
call25.000.000.250.101.09113.000.000.042-0.0160.003
call26.000.002.154.701.31233.000.000.038-0.0190.002
call27.000.002.150.041.4214.000.000.036-0.0190.002
call28.000.000.300.001.4020.000.000.034-0.0170.002
call29.000.000.053.751.6392.000.000.032-0.0200.002
call30.000.000.750.201.71782.000.000.031-0.0200.002
call31.000.002.150.051.8062.000.000.029-0.0210.002
call32.000.002.152.801.8923040.000.028-0.0210.002
call33.000.002.152.601.97588.000.000.027-0.0210.002
call34.000.002.152.252.0546630.000.027-0.0210.002
call35.000.000.752.001.9751730.000.026-0.0190.002
put13.000.000.100.202.06629.000.00-0.107-0.0620.005
put14.000.002.150.001.3780.000.00-0.083-0.0350.004
put15.000.000.500.101.09312.000.00-0.102-0.0330.005
put16.000.002.150.400.81317.000.00-0.131-0.0290.006
put17.000.050.150.320.5291420.00-0.291-0.0530.009
put18.000.001.100.451.1164,3452.00-0.448-0.0580.011
put19.000.003.201.642.55852.000.00-0.547-0.0930.011
put20.000.104.102.752.7974,2850.00-0.661-0.0790.010
put21.000.854.603.702.61477.000.00-0.932-0.0120.004
put22.002.556.003.503.25923.000.00-0.943-0.0130.003
put23.003.507.003.403.49719.000.00-0.950-0.0140.003
put24.003.807.903.003.6180.000.00-0.955-0.0150.003
put25.004.708.903.153.8210.000.00-0.959-0.0150.002
put26.006.009.906.473.5021160.00-0.962-0.0160.002
put27.006.7010.907.204.1860.000.00-0.964-0.0160.002
put28.007.7011.900.004.3520.000.00-0.966-0.0160.002
put29.008.9012.900.004.5060.000.00-0.968-0.0170.002
put30.009.7013.900.004.6560.000.00-0.969-0.0170.002
put31.0010.7014.900.004.7970.000.00-0.971-0.0170.002
put32.0011.7015.900.004.9310.000.00-0.972-0.0170.002
put33.0012.9017.000.005.1620.000.00-0.973-0.0180.002
put34.0013.7018.000.005.2840.000.00-0.973-0.0180.002
put35.0014.7019.000.005.4020.000.00-0.974-0.0180.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-238-KCurrent report2026-10-23SEC
2026-09-248-KCurrent report2026-09-24SEC
2026-09-118-KCurrent report2026-09-11SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-07SCHEDULE 13GSEC
2026-08-05144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC
2026-06-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-05-298-KCurrent report2026-05-29SEC
2026-05-274Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-26144Filing for proposed sale of securities under Rule 144.SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-05-054Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-054Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-018-KCurrent report2026-04-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100069.34K1
2026-090000
2026-0800587.24K2
2026-0700432.66K1
2026-060000
2026-0500219.81K3
2026-040083.01K2
2026-0300607.24K7
2026-0200162.49K1
2026-010000
2025-120000
2025-11001.01M3

Institutional holders

Manager% owned
BAKER BROS. ADVISORS LP25.06%
BlackRock, Inc.13.15%
VANGUARD PORTFOLIO MANAGEMENT LLC5.16%
STATE STREET CORP4.44%
RTW INVESTMENTS, LP4.17%
VANGUARD CAPITAL MANAGEMENT LLC3.37%
GEODE CAPITAL MANAGEMENT, LLC1.96%
DIMENSIONAL FUND ADVISORS LP1.95%
Palo Alto Investors LP1.67%
GOLDMAN SACHS GROUP INC1.51%

Funds

Fund% owned
iShares Core S&P Small-Cap ETF4.46%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.38%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.32%
iShares Russell 2000 ETF1.96%
SMALLCAP World Fund Inc1.75%
VANGUARD SMALL-CAP INDEX FUND1.72%
VANGUARD SMALL-CAP GROWTH INDEX FUND0.99%
VANGUARD EXTENDED MARKET INDEX FUND0.85%
Fidelity Small Cap Index Fund0.82%
iShares Biotechnology ETF0.70%

OakChart. ACAD. Cached 15 minutes. Terms